Palvella Therapeutics, Inc. Share-based Payment Arrangement, Expense
Palvella Therapeutics, Inc. (PVLA) reported Share-based Payment Arrangement, Expense of $5.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-04
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $5.16M, a 259.73% increase year-over-year.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $3.38M, a 208.59% increase year-over-year.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.08M, a 677.61% increase year-over-year.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.79M, a 799.50% increase year-over-year.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $6.40M, a 671.20% increase from fiscal 2024.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $830.00K, a 37.65% increase from fiscal 2023.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $603.00K, a 86.30% decline from fiscal 2022.
- Palvella Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $4.40M, a 15.59% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.16M 10-Q · filed 2026-08-04 | $8.53M 10-Q · filed 2026-08-04 | $10.62M derived: sum of 3 quarters · filed 2026-08-04 | $12.40M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $3.38M 10-Q · filed 2026-05-07 | $5.46M derived: sum of 2 quarters · filed 2026-05-07 | $7.25M derived: sum of 3 quarters · filed 2026-05-07 | $8.68M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.87M derived: sum of 2 quarters · filed 2026-03-31 | $5.31M derived: sum of 3 quarters · filed 2026-08-04 | $6.40M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.79M 10-Q · filed 2025-11-12 | $3.22M derived: sum of 2 quarters · filed 2026-08-04 | $4.32M 10-Q · filed 2025-11-12 | $4.58M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $1.43M 10-Q · filed 2026-08-04 | $2.53M 10-Q · filed 2026-08-04 | $2.79M derived: sum of 3 quarters · filed 2026-08-04 | $2.99M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $1.09M 10-Q · filed 2026-05-07 | $1.36M derived: sum of 2 quarters · filed 2026-05-07 | $1.56M derived: sum of 3 quarters · filed 2026-05-07 | $1.78M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $467.00K derived: sum of 2 quarters · filed 2026-03-31 | $684.00K derived: sum of 3 quarters · filed 2026-03-31 | $830.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $199.00K 10-Q · filed 2025-11-12 | $416.00K derived: sum of 2 quarters · filed 2025-11-12 | $562.00K 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | $217.00K 10-Q · filed 2025-08-14 | $363.00K 10-Q · filed 2025-08-14 | |||||
| 2024-03-31 | $146.00K 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | $603.00K 10-K · filed 2025-03-31 | $3.35M 10-K · filed 2024-03-29 | |||||
| 2022-12-31 | $4.40M 10-K · filed 2024-03-29 | ||||||
| 2021-12-31 | $5.21M 10-K · filed 2023-03-31 | ||||||
| 2020-12-31 | $5.09M 10-K · filed 2022-03-02 | ||||||
| 2019-12-31 | $5.37M 10-K · filed 2021-03-31 | ||||||
| 2018-12-31 | $4.94M 10-K · filed 2020-03-13 | ||||||
| 2017-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $1.73M derived: sum of 2 quarters · filed 2019-03-18 | $2.29M derived: sum of 3 quarters · filed 2019-03-18 | $3.05M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $649.95K 10-Q · filed 2017-11-13 | $1.21M derived: sum of 2 quarters · filed 2017-11-13 | $1.96M 10-Q · filed 2017-11-13 | $2.44M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2017-06-30 | $559.88K 10-Q · filed 2017-08-11 | $1.31M 10-Q · filed 2017-08-11 | $1.79M derived: sum of 3 quarters · filed 2018-03-15 | $2.24M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2017-03-31 | $752.19K 10-Q · filed 2017-05-15 | $1.23M derived: sum of 2 quarters · filed 2018-03-15 | $1.68M derived: sum of 3 quarters · filed 2018-03-15 | $2.29M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-12-31 | $478.66K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $924.77K derived: sum of 2 quarters · filed 2018-03-15 | $1.54M derived: sum of 3 quarters · filed 2018-03-15 | $1.91M 10-K · filed 2018-03-15 | $1.91M 10-K · filed 2017-03-30 | ||
| 2016-09-30 | $446.11K 10-Q · filed 2017-11-13 | $1.06M derived: sum of 2 quarters · filed 2017-11-13 | $1.43M 10-Q · filed 2017-11-13 | $1.77M derived: sum of 4 quarters · filed 2017-11-13 | |||
| 2016-06-30 | $611.85K 10-Q · filed 2017-08-11 | $980.23K 10-Q · filed 2017-08-11 | $1.32M derived: sum of 3 quarters · filed 2017-08-11 | $1.66M derived: sum of 4 quarters · filed 2017-08-11 | |||
| 2016-03-31 | $368.38K 10-Q · filed 2017-05-15 | $709.85K derived: sum of 2 quarters · filed 2017-05-15 | $1.05M derived: sum of 3 quarters · filed 2017-05-15 | $1.32M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2015-12-31 | $341.47K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $679.26K derived: sum of 2 quarters · filed 2017-03-30 | $947.30K derived: sum of 3 quarters · filed 2017-03-30 | $1.16M 10-K · filed 2017-03-30 | |||
| 2015-09-30 | $337.79K 10-Q · filed 2016-11-10 | $337.79K 10-Q · filed 2015-11-13 | $605.83K derived: sum of 2 quarters · filed 2016-11-10 | $823.16K 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | $268.04K 10-Q · filed 2016-08-11 | $485.37K 10-Q · filed 2016-08-11 | $485.38K 10-Q · filed 2015-08-13 | ||||
| 2015-03-31 | $217.34K 10-Q · filed 2016-05-12 | ||||||
| 2014-12-31 | $571.38K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |